nominally significantP = 0.046
The P ‐value for the interaction of prior HF was nominally significant ( P = 0.046); however, this was not controlled for multiple comparisons. 3.4 Time to first occurrence of MACE in the phase 3a glycaemic efficacy trials In the combined SUSTAIN and PIONEER glycaemic efficacy trials, the incidence rates for MACE were 0.7 and 0.9 events per 100 subject‐years with semaglutide and comparator, respectively (HR 0.85 [95% CI 0.55, 1.33]; Figure 4 ).